Evidence map›Paper›PMID 42703424›Full record

ArticleJournal of gastrointestinal oncology2026

Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior.

Shan Liu, Zeng Zhang, Qian An, Yue Jia, Qin Su, Dezhi Zhu, Likun Luan, Hongying Yang, Zhirui Chuan, Xinyuan Liu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shan Liu *Department of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Zeng Zhang *Department of Internal Medicine, Puning Overseas Chinese Hospital, Puning, China.
Qian An *Department of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Yue Jia *Department of Gynecological Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kumming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
Qin Su *Department of Otolaryngology, Kunming First People's Hospital, Kunming, China.
Dezhi Zhu *Department of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Likun Luan *Department of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Hongying YangDepartment of Ultrasound Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kumming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
Zhirui ChuanDepartment of Ultrasound Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kumming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
Xinyuan LiuPLA Air Force Hospital of the Western Theater Command, Chengdu, China.
Siyu WangDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Yanyan LiuDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Fenglian FuDepartment of Geriatric Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kumming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
Qiong SunDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Luyao MaDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Juanrong YangDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Yiming ZhangDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Mingzhi DuanDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Peijun YaoDepartment of Colorectal Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kumming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China.
Changqing YangDepartment of Pulmonary Diseases, Xiangyun County Traditional Chinese Medicine Hospital, Dali, China.
Yiming XingDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Hongmei ShenDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.
Yongxin JiangDepartment of Combination of Traditional Chinese and Western Medicine, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital, Kunming Medical University, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) is the most prevalent and malignant gastrointestinal tract tumor. The incidence remains high, and the issue of resistance to radiotherapy and chemotherapy is prominent. The aims were therefore to establish a model for radio- and chemoresistance in CRC, elucidating the underlying mechanism that could help identify measures to reverse its resistance and improve the clinical efficacy of radiotherapy and chemotherapy. Methods: A HCT116 and HT29 cell model of radiotherapy and chemotherapy resistance in CRC was established by simulating clinical high-dose shock therapy as a key in vitro method. For the in vivo animal studies, healthy 6-week-old BALB/c nude mice (both genders) were used. The changes in its biological behavior were studied to provide a theoretical basis for improving the efficacy of radiotherapy and chemotherapy in clinical practice. Results: We successfully established a CRC cell line with radio- and chemoresistance, and it exhibited stronger potential for cell proliferation, colony formation, invasion, and migration than its parental cell line. Furthermore, in nude mouse models, the resistant cells showed stronger tumorigenicity and stronger liver and lung metastasis ability than the parental cells. Conclusions: This research helps elucidate the molecular mechanism of chemo- and radiotherapy resistance in CRC and can potentially improve the molecular diagnosis and gene therapy of CRC.

Indexed as

biological behaviorcell modelChemoradiation-resistancecolorectal cancer (CRC)establishment

Identifiers

PMID42703424
PMCPMC13546525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.